Sun Pharma records turnaround Q1FY22 numbers, above estimates Consolidated sales from operations stood at Rs 9718.54 crore, registering a growth of 29% over Q1 FY21. The drug company posted a profit before tax of Rs 1,804.2 crore in Q1 FY22 as compared to a pre tax loss of Rs 2183.9 crore registered in Q1 FY21. EBITDA stood at Rs 2,771.8 crore, up by 59% year on year. Meanwhile, EBITDA margin came to 28.7% in Q1 FY22. Consolidated R&D; investment for Q1FY22 stood at Rs 592.6 crore as compared to Rs 420.6 crore in Q1 FY21. It has report profit after tax of Rs 1901.36 crore in Q1 FY22 as compared to a...